Join
Live feed
·
PRReleasevia Quantisnow
NewcelX Ltd. logo

NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio

ByQuantisnow·Wall Street's wire, on your screen.
NCEL· NewcelX Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NCEL (NewcelX Ltd.) and more on Quantisnow.